Sonova Holding AG (SONVY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sonova Holding AG (SONVY) trades at $60.40 with AI Score 50/100 (Grade B). Sonova Holding AG is a leading provider of hearing care solutions, specializing in hearing instruments and cochlear implants. Market cap: $17.9B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026SONVY stock analysis for 2026: Analysts have set a consensus price target of $55.00 for Sonova Holding AG, suggesting 8.9% downside from the current price of $60.40. The AI MoonshotScore is 50/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
SONVY: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Sonova Holding AG (SONVY) Healthcare & Pipeline Overview
Sonova Holding AG excels in designing and distributing innovative hearing care solutions, including hearing instruments and cochlear implants, leveraging a strong brand portfolio and extensive distribution network across multiple regions.
What Is the Investment Thesis for SONVY?
Sonova Holding AG's investment thesis is supported by its robust financial metrics, including a market capitalization of $17.9B and a P/E ratio of 21.9, indicating solid growth potential. The company boasts a profit margin of 15% and a gross margin of 73%, reflecting efficient operations and strong pricing power. Key growth catalysts include the increasing global prevalence of hearing loss, projected to rise significantly in the coming years, and the expansion of its product offerings in the cochlear implant segment. Additionally, Sonova's strategic focus on wireless communication technologies and audiological care services enhances its competitive edge. Ongoing investments in research and development are expected to drive innovation and further solidify its market position. However, potential risks include regulatory challenges and competition from emerging players in the hearing care market.
Based on FMP financials and quantitative analysis
SONVY Key Highlights
Market capitalization of $17.9B, reflecting strong investor confidence.
- P/E ratio of 21.9, indicating a premium valuation compared to industry peers.
- Profit margin of 15.0%, showcasing effective cost management and operational efficiency.
- Gross margin of 73.0%, significantly higher than the industry average, highlighting strong pricing power.
- Dividend yield of 2.19%, providing a steady income stream for investors.
Who Are SONVY's Competitors?
SONVY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SARTF Sartorius AG | $212.80 | +0.00% | $14.7B | 51 |
| GIKLY Grifols, S.A. | $5.10 | +0.00% | $13.4B | 48 |
| SNNUF Smith & Nephew plc | $15.48 | +0.00% | $13.0B | 47 |
| FMCQF Fresenius Medical Care AG & Co. KGaA | $51.44 | +0.00% | $13.8B | 46 |
| SBMFF Sino Biopharmaceutical Limited | $0.65 | +0.00% | $11.6B | 54 |
| ABMD Abiomed, Inc. | $381.02 | +0.00% | $17.2B | 60 |
| ZBH Zimmer Biomet Holdings, Inc. | $100.72 | -0.02% | $19.5B | 78 |
| STE STERIS plc | $236.91 | +1.95% | $24.0B | 85 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SONVY's Key Strengths?
Leading position in the hearing care market with strong brand equity.
- Robust financial performance with high profit and gross margins.
- Extensive distribution network enhancing product accessibility.
- Commitment to innovation and R&D driving product development.
What Are SONVY's Weaknesses?
Dependence on a limited number of key brands for revenue.
- Exposure to regulatory changes in healthcare markets.
- Potential challenges in adapting to rapidly changing technology trends.
What Are the Key Risks for SONVY?
Regulatory challenges in various international markets.
- Intense competition from both established and new entrants in the hearing care sector.
- Economic downturns affecting consumer spending on healthcare products.
- Fluctuations in currency exchange rates impacting financial performance.
- Supply chain disruptions affecting product availability.
What Are the Growth Opportunities for SONVY?
- Growth opportunity 1: The global hearing aids market is expected to grow at a CAGR of 7.5% from 2023 to 2027, driven by the increasing prevalence of hearing loss and advancements in technology. Sonova's focus on developing innovative, rechargeable hearing aids positions it to capture a significant share of this expanding market.
- Growth opportunity 2: The cochlear implants segment is projected to grow significantly, with a market size expected to reach $4 billion by 2026. Sonova's Advanced Bionics brand is well-regarded for its cutting-edge technology, providing a competitive edge in this lucrative market.
- Growth opportunity 3: Expansion into emerging markets such as Asia-Pacific, where the demand for hearing care solutions is on the rise due to a growing middle class and increasing healthcare access. Sonova's strategic investments in these regions are expected to drive revenue growth over the next five years.
- Growth opportunity 4: The integration of wireless technology into hearing aids and audiological services presents a substantial growth avenue. As consumers increasingly seek connectivity and convenience, Sonova's innovative products are likely to attract a broader customer base.
- Growth opportunity 5: Collaborations and partnerships with healthcare providers and technology firms to enhance service delivery and product development. Such strategic alliances can lead to improved market penetration and customer engagement, further driving growth.
What Are SONVY's Competitive Advantages?
- Strong brand recognition with established names like Phonak and Advanced Bionics.
- Extensive distribution network with approximately 3,600 stores and clinics worldwide.
- Commitment to innovation and R&D, leading to advanced product offerings.
- High gross margins indicating strong pricing power and operational efficiency.
- Diverse product portfolio catering to various segments of the hearing care market.
What Does SONVY Do?
Founded in 1947 and headquartered in Stäfa, Switzerland, Sonova Holding AG has established itself as a prominent player in the hearing care industry. Originally known as Phonak Holding AG, the company rebranded to Sonova in 2007 to reflect its broader vision in the hearing healthcare market. Sonova operates through two primary segments: Hearing Instruments and Cochlear Implants. The Hearing Instruments segment includes a range of products such as rechargeable hearing aids, wireless communication devices, and audiophile headphones, marketed under well-known brands like Phonak, Unitron, and Hansaton. The Cochlear Implants segment focuses on advanced hearing solutions through its Advanced Bionics brand. Sonova also provides consumer hearing products under the Sennheiser brand and audiological care services through a network of brands including AudioNova, Audium, and Boots Hearingcare. With approximately 3,600 stores and clinics worldwide, Sonova serves a diverse customer base across the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company’s commitment to innovation and quality has positioned it as a leader in the global hearing care market, addressing the needs of both adults and children with hearing impairments.
What Products and Services Does SONVY Offer?
- Design and manufacture hearing care solutions for adults and children.
- Offer a wide range of hearing instruments, including rechargeable hearing aids.
- Provide cochlear implants through the Advanced Bionics brand.
- Distribute consumer hearing products under the Sennheiser brand.
- Deliver audiological care services through a network of clinics and stores.
- Sell products through independent distributors globally.
How Does SONVY Make Money?
- Generate revenue through the sale of hearing instruments and cochlear implants.
- Offer audiological care services, enhancing customer engagement and loyalty.
- Leverage a diverse brand portfolio to capture various market segments.
- Utilize a global distribution network to reach customers in multiple regions.
- Invest in research and development to drive innovation and product differentiation.
What Industry Does SONVY Operate In?
The medical devices industry, particularly in hearing care, is experiencing significant growth due to an aging population and increasing awareness of hearing health. The global hearing aids market is projected to reach approximately $10 billion by 2027, driven by technological advancements and rising demand for innovative solutions. Sonova Holding AG is well-positioned within this expanding market, competing with key players such as Sartorius AG, Grifols, S.A., and Smith & Nephew plc. The company's diverse product portfolio and strong brand recognition provide a competitive advantage in capturing market share.
Who Are SONVY's Key Customers?
- Individuals with hearing impairments, including both adults and children.
- Healthcare providers and audiologists seeking reliable hearing care solutions.
- Retail partners and independent distributors across various regions.
- Consumers looking for high-quality audiophile headphones and communication devices.
- Organizations and institutions focused on improving hearing health.
Sonova Holding AG (SONVY) Valuation Context
Valued at $17.9B, SONVY is classified as a large-cap stock. Relative to its peer group, SONVY's quantitative score of 50/100 is roughly in line with the peer average of 49/100.
SONVY Revenue & Earnings Trend
In Q1 2026, SONVY generated $1.81B in top-line revenue, marking a sequential increase of 2.0%. The company recorded net income of $358.0M, with diluted EPS of $1.19. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, SONVY averaged $0.91 in diluted EPS.
Company Profile
Sonova Holding AG operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Stäfa, CH. The company is led by CEO Eric Bernard. SONVY has traded publicly since 2011.
Key Financial Metrics
Return on equity for Sonova Holding AG stands at 21.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 9.5%, showing how much profit it generates from its asset base. SONVY trades at a trailing price-to-earnings ratio of 21.87, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 5.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.5%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Sonova Holding AG's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 5.88 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Sonova Holding AG has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 1.7% below estimates on average.
Forward Outlook
Wall Street analysts project Sonova Holding AG revenue of about $3.79B for fiscal 2026, with EPS near $1.95. The estimate reflects 9 contributing analysts.
SONVY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Sonova's growth potential, indicating that key stakeholders believe in the company's future.
- Community sentiment has been increasingly positive, with discussions highlighting Sonova's innovative hearing solutions and strong brand reputation.
- Market perception has shifted favorably as demand for hearing aids rises, driven by an aging population and increased awareness of hearing health.
- Recent product launches have generated buzz, positioning Sonova as a leader in technology advancements within the hearing aid sector.
Bear Case
- Concerns over supply chain disruptions have surfaced, potentially impacting Sonova's ability to meet growing demand in a timely manner.
- Some community members express skepticism about the sustainability of recent growth, citing competitive pressures in the hearing aid market.
- Recent regulatory changes in key markets have raised uncertainty, leading to caution among investors and analysts alike.
- While sentiment is generally positive, a few bearish voices highlight potential valuation concerns if growth does not meet heightened expectations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.81B | $358M | $1.19 |
| Q3 2025 | $1.78B | $185M | $0.62 |
| Q1 2025 | $2.03B | $332M | $1.11 |
| Q3 2024 | $1.83B | $209M | $0.70 |
Based on FMP financials and quantitative analysis
SONVY Latest News
No recent news available for SONVY.
SONVY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SONVY.
Price Targets
Consensus target: $55.00
SONVY MoonshotScore
What does this score mean?
The MoonshotScore rates SONVY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Eric Bernard
CEO
Eric Bernard has extensive experience in the healthcare and medical devices sectors. He holds a degree in Business Administration and has held various leadership roles within the industry prior to joining Sonova. His strategic vision and operational expertise have contributed significantly to the company's growth and innovation.
Track Record: Under Eric Bernard's leadership, Sonova has expanded its product portfolio and enhanced its market presence globally. His focus on innovation and customer-centric strategies has led to significant improvements in operational efficiency and financial performance.
Sonova Holding AG ADR Information Unsponsored
An American Depositary Receipt (ADR) represents shares in a foreign company, allowing U.S. investors to trade shares of foreign companies on U.S. exchanges. Sonova Holding AG's ADR, SONVY, facilitates investment in its shares without the complexities of foreign stock transactions.
- Home Market Ticker: SONV trades on the OTC market in the United States, with its primary stock exchange located in Switzerland.
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SONV
SONVY OTC Market Information
The OTC Other tier includes stocks that trade on the Over-the-Counter market but do not meet the requirements for listing on major exchanges like NYSE or NASDAQ. This tier often includes foreign companies like Sonova that seek to provide U.S. investors with access to their shares without the full regulatory burden of major exchanges.
- OTC Tier: OTC Other
- Limited trading volume may result in higher volatility and less price stability.
- Potential lack of transparency compared to companies listed on major exchanges.
- Currency fluctuations may impact the value of investments.
- Regulatory risks associated with foreign companies operating in the U.S. market.
- Investor sentiment may be influenced by geopolitical events affecting the home market.
- Review Sonova's financial statements and performance metrics.
- Analyze the company's competitive positioning and market trends.
- Assess the impact of currency fluctuations on investment returns.
- Understand the regulatory environment for foreign companies in the U.S.
- Evaluate the liquidity and trading volume of the ADR.
- Established brand reputation in the hearing care industry.
- Transparent financial reporting and disclosures.
- Presence of a strong management team with industry experience.
What Investors Ask About Sonova Holding AG (SONVY) — Healthcare
What does the AI Score mean for SONVY?
SONVY holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Sonova Holding AG is a leading provider of hearing care solutions, specializing in hearing instruments and cochlear implants. With a strong global presence and a diverse product portfolio, …
What does Sonova Holding AG do?
Sonova Holding AG specializes in designing, developing, and distributing hearing care solutions for both adults and children. The company operates through two main segments: Hearing Instruments and Cochlear Implants, offering a diverse range of products including rechargeable hearing aids, cochlear implants, and audiological care services through a network of clinics and stores globally.
What are the main risks for SONVY?
Sonova Holding AG faces several risks, including regulatory challenges that could affect product approvals and market access. Additionally, the company operates in a highly competitive landscape, where both established and emerging players are vying for market share. Economic downturns may also impact consumer spending on hearing care products, while fluctuations in currency exchange rates can affect financial performance.
How does Sonova Holding AG manage patent expiration risks?
Sonova Holding AG actively manages patent expiration risks through continuous investment in research and development to innovate and enhance its product offerings. The company focuses on lifecycle management strategies, such as developing next-generation products and expanding its service capabilities, to maintain market competitiveness even as patents expire.
What are the key factors to evaluate for SONVY?
Sonova Holding AG (SONVY) holds an AI score of 50/100 (moderate). P/E: 21.9x vs the S&P 500's ~20-25x. Analysts target $55.00 (-9%). Not financial advice.
How frequently does SONVY data refresh on this page?
SONVY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SONVY's recent stock price performance?
Sonova Holding AG (SONVY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading position in the hearing care market with strong brand equity. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SONVY overvalued or undervalued right now?
Sonova Holding AG (SONVY) trades at 21.9x earnings. Analysts target $55.00 (-9%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SONVY before investing?
Before investing in Sonova Holding AG (SONVY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.